P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)

Nicole Wong; Namrata Nayar; Nicola Lawrence; Martin Stockler; Andrew Martin; Sonia Yip; Annie Yeung; Michael Friedlander; Danish Mazhar; Farzana Pashankar; David Quinn; Roderick Walker; Mark Winstanley; Andrew Weickhardt; Fritha Hanning; Amanda Stevanovic; Ian Davis; Guy Toner; Peter Grimison

Conference Proceedings

P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)

Nicole Wong, Namrata Nayar, Nicola Lawrence, Martin Stockler, Andrew Martin, Sonia Yip, Annie Yeung, Michael Friedlander, Danish Mazhar, Farzana Pashankar, David Quinn, Roderick Walker, Mark Winstanley, Andrew Weickhardt, Fritha Hanning, Amanda Stevanovic, Ian Davis, Guy Toner, Peter Grimison

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2017

DOI: 10.1200/jco.2025.43.5_suppl.tps653

Abstract

TPS653 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 is standard first-line chemotherapy for intermediate and poor-risk metastatic GCT. Acceleration of standard chemotherapy regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP is the first international, randomized trial of chemotherapy for intermediate and poor-risk metastatic GCT to include adults and children of both sexes. It aims to determine the superiority of accelerated BEP versus standard BEP in this setting. Methods: This open label, randomized, phase 3 trial is conducted seamlessly in 2 stages..

View full abstract